Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: A phase i study

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 7, 2012, Pages 1113-1120

  Nitsche, Mirko ^a,b   Christiansen, Hans ^b,c   Lederer, Katinka ^b,d   Griesinger, Frank ^b,e   Schmidberger, Heinz ^b,f   Pradier, Olivier ^b,g  

^a Center of Radiation Oncology   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Sykehuset Innlandet HF ^*  (Norway)

^e KLINIKUM OLDENBURG   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g BREST UNIVERSITY HOSPITAL   (France)

Author keywords

Concurrent fludarabine and radiotherapy; Fludarabine; Locally advanced inoperable NSCLC; NSCLC; Nucleoside analogue; Phase I study; Radiochemotherapy in stage III NSCLC; Radiotherapy

Indexed keywords

CORTISONE; FLUDARABINE; FLUDARABINE PHOSPHATE;

ACUTE TOXICITY; ADULT; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DYSPNEA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SKIN TOXICITY; THROMBOCYTOPENIA; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; VIDARABINE;

EID: 84864358937     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1185-3     Document Type: Article

References (48)

1. Abacioglu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS (2005) Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer. BMC Cancer 5:71
2. Blanco R, Solé J, Montesinos J, Mesia C, Algara M et al. (2008) Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study. Lung Cancer 62(1):62-71
3. Brockman RW, Cheng YC, Schabel FM, Montgomery JA (1980) Metabolism and chemotherapeutic activity of 9-b-D-arabinofuranosyl- 2-Fuoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610-3615 (Pubitemid 10003759)
4. Buccheri G, Ferrigno D (1996) Therapeutic options for regionally advanced non-small cell lung cancer. Lung Cancer 14:281-300 (Pubitemid 26191590)
5. Cheson BD (1995) Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431-2448
6. Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK et al. (2005) Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol 3(1):59-67
7. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group [RTOG] and the European organization for research and treatment of cancer [EORTC]. Int J Radiat Oncol Biol Phys 31:1341-1346
8. Curran WJ Jr (2002) Combined-modality therapy for inoperable nonsmall- cell lung cancer using gemcitabine. Clin Lung Cancer 3(Suppl1):S17-S21 (Pubitemid 34461172)
9. Dahlberg WK, Little JB (1992) Differential sensitization of human tumor cells by Ara-A to X-irradiation and its relationship to inherent radioresponse. Radiat Res 130:303-308
10. Edelman MJ, Suntharalingam M, Burrows W, Kwong KF, Mitra N et al. (2008) Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg 86(3):903-910
11. Frank DA, Mahajan S, Ritz J (1999) Fludarabine-induced imunosuppression is associated with inhibition of STAT1 signaling. Nat Med 5:444-447 (Pubitemid 29180586)
12. Furuse K, Fukuoka M, Kawahara, Nishikawa H, Takada YM et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17(9):2692-2699 (Pubitemid 29415225)
13. Ginsberg RJ (1995) Neoadjuvant [induction] treatment for non-small cell lung cancer. Lung Cancer 12(Suppl 2):S33-S40
14. Gregoire V, Hittelmann WN (1997) Nucleoside analogs as radiosensitizing agents. In: Cheson BD, Keating MJ, Plunkett W (eds) Nucleoside analogues in cancer therapy. Marcel Dekker, New York, pp 315-358
15. Gregoire V, Hunter N, Brock W, Milas L, Plunkett W, Hittelman WN (1994a) Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single dose irradiation. Int J Radiat Oncol Biol Phys 30(2):363-371 (Pubitemid 24309739)
16. Gregoire V, Hunter N, Milas L, Brock WA, Plunkett W, Hittelman WN (1994b) Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res 54(2):468-474 (Pubitemid 24053187)
17. Gregoire V, Van NT, Stephens LC, Brock WA, Milas L et al. (1994c) The role of fludarabine-induced apoptosis and cell cycle synchronisation in enhanced murine tumor radiation response in vivo. Cancer Res 54(23):6201-6209 (Pubitemid 24378654)
18. Gregoire V, Ang KK, Rosier JF, Beauduin M, Garden AS et al (2002) A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamos cell carcinoma. Radiother Oncol 63(2):187-193 (Pubitemid 34628406)
19. Huang P, Chubb S, Plunkett W (1990) Termination of DNA synthesis by 9-b-D-arabinofuranosyl-2-Fluoroadenine: a mechanism for cytotoxicity. J Biol Chem 265:16617-16625
20. Jayanth RV, Hittelman WN (1991) 9-b-D-arabinofuranosyl-2-Fluoroadenine inhibits both the slow and fast components of chromosome repair. In: Chapman JD, Dewey WC, Whitemore GF (eds) Radiation research: a twentieth century perspective. Academic Press, San Diego, pp411
21. Jeremic B, Jevremovic S, Mijatovic L, Milisavljevic S (1993) Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer. Cancer 71(11):3732-3736 (Pubitemid 23152691)
22. Johnson S, Smith AG, Löffler H, Osby E, Juliusson G et al (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamid, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347:1432-1438 (Pubitemid 26161205)
23. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C et al (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25 (Pubitemid 19187405)
24. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J et al. (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26(15):2450-2456
25. Kim JH, Alfieri A, Kim SH, Fuks Z (1986) The potentiation of radiation response on murine tumor by Fludarabine phosphate. Cancer Lett 31(1):69-76 (Pubitemid 16050787)
26. Kosmidis P, Fountzilas G, Baka S, Samantas E, Dimopoulos AM et al. (2007) Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in nonoperable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study. Anticancer Res 27(6C):4391-4395
27. Lathan B, Diehl V, Clark GM, von Hoff DD (1988) Cytotoxic activity of 9-b-D-arabinofuranosyl-2-Fluoroadenine-5-monophosphate (Fludarabine) in a human tumor cloning system. Eur J Cancer 24:1891-1895 (Pubitemid 19022381)
28. Laurent D, Pradier O, Schmidberger H, Rave-Fränk M, Frankenberg D, Hess CF (1998) Radiation rendered more cytotoxic by Fludarabine monophosphate in a human oropharynx carcinoma cell-line than in fetal lung Fibroblasts. J Cancer Res Clin Oncol 124:485-492 (Pubitemid 28474158)
29. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423
30. Li L, Liu X, Glassman AB, Keating MJ, Stros M et al. (1997) Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 57(8):1487-1494 (Pubitemid 27175565)
31. Malaise EP, Debieu D, Chavaudra N, Grinfeld S (1989) The effect of the oxic cell sensitizer b-Ara-A on human Fibroblasts in plateau and in exponential growth phases. Int J Radiat Oncol Biol Phys 16:1257-1259 (Pubitemid 19137224)
32. Marino P, Preatoni A, Cantoni A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a metaanalysis. Cancer 76:593-601
33. Mittelmann A, Ashikari R, Ahmed T, Savona S, Arnold P, Arlin Z (1988) Phase II trial of fludarabine phosphate (f-ara-AMP) in patients with advanced breast cancer. Cancer Chemother Pharmacol 22(1):63-64
34. Naito Y, Kubota K, Nihei K, Fujii T, Yoh K et al. (2008) Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer. J Thorac Oncol 3(6):617-622 (Pubitemid 351787306)
35. Nakamura M, Koizumi T, Hayasaka M, Yasou M, Tsushima K et al. (2008) Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 63(6):1091-1096
36. Nitsche M, Christiansen H, Hermann RM et al. (2008) The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro. Int J Radiat Biol 84(8):643-657
37. O'Rourke N, Rouge I, Figuis M, Farre Bernado N, Macbeth F (2010) Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 6:CD002140
38. Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M et al (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59:1874-1881 (Pubitemid 17072411)
39. Plunkett W, Chubb S, Alexander L, Montgomery J (1980) Comparison of the toxicity and metabolism of 9-b-D-arab-inofuranosyl- 2-Fluoroadenine and 9-b-D-arabinofuransyladenine in human lymphoblastoid cells. Cancer Res 40:2349-2355 (Pubitemid 10082249)
40. Plunkett W, Huang P, Ghandi V (1990) Metabolism and action of Fludarabine phosphate. Semin Oncol 17(5Suppl8):3-17 (Pubitemid 20356424)
41. Plunkett W, Ghandi V, Huang P, Robertson LE, Yang LY et al. (1993) Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20(5Suppl7):2-12 (Pubitemid 23333771)
42. Pritchard RS, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: a metaanalysis. Ann Intern Med 125(9):723-729 (Pubitemid 126450359)
43. Sause WT, Scott C, Taylor S, Johnson D, Livingston R et al. (1995) Radiation Therapy Oncology Group [RTOG] 88-08 and Eastern Cooperative Oncology Group [ECOG] 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall- cell lung cancer. J Natl Cancer Inst 87:198-205
44. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530
45. Seung SK, Ross HJ (2009) Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer. Int J Radiat Oncol Biol Phys 73(3):802-809
46. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350(4):379-392 (Pubitemid 38101633)
47. van Putten JW, Price A, van der Leest AH, Gregor A, Little FA et al. (2003) A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 9(7):2472-2477 (Pubitemid 36842086)
48. Weiss GB, Metch B, von Hof DD, Taylor SA, Saiers JH (1987) Phase II trial of fludarabine phosophate in patients with head and neck cancer. A southwest oncology group study. Cancer Treat Rep 71:1313-1314